TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04698915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug GC4711
Description: 15 Minute IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 Minute IV Infusion
Study: NCT05208346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meals
Description: Mixed meals enriched with either 25 or 50 g of canola or coconut oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meals
Description: Mixed meals enriched with either 25 or 50 g of canola or coconut oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meals
Description: Mixed meals enriched with either 25 or 50 g of canola or coconut oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meals
Description: Mixed meals enriched with either 25 or 50 g of canola or coconut oil
Study: NCT06352125

Intervention type: DIAGNOSTIC_TEST
Intervention: Clauss Fibrinogen
Description: Diagnostic Test: Clauss Fibrinogen Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days.
Study: NCT05192395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1525
Description: DWJ1525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1525
Description: DWJ1525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001
Study: NCT05305677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NMN intervention
Description: NMN capsules (total of 600mg/day) for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NMN-free placebo capsules for 8 weeks
Study: NCT05419310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation - core strengthening
Description: Physical rehabilitation based on core strengthening

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation - core strengthening
Description: Physical rehabilitation based on core strengthening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation - core strengthening
Description: Physical rehabilitation based on core strengthening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation - rehabilitation pilates
Description: Physical rehabilitation based on rehabilitation pilates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic taping application
Description: Application of elastic taping

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Elastic taping application
Description: Application of elastic taping
Study: NCT06220812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser ,pulsed electromagnetic field .
Description: LLL ,ASA via Alessandro Volta, 9 .36057 Arcugnano- Italy. With 905-nm wavelength, and maximum power output of 500 mW, laser spot of approximately 1 cm2 .~PEMF, ASA, Easy teraza serie (ETS), Italy 2011, its code F9020087 and 230 its voltage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser ,pulsed electromagnetic field .
Description: LLL ,ASA via Alessandro Volta, 9 .36057 Arcugnano- Italy. With 905-nm wavelength, and maximum power output of 500 mW, laser spot of approximately 1 cm2 .~PEMF, ASA, Easy teraza serie (ETS), Italy 2011, its code F9020087 and 230 its voltage.
Study: NCT06190288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional care model
Description: A newly developed care model to support frail older adults during their transition from hospital to home.
Study: NCT05221177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TR-30
Description: Suspension training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TR-45
Description: Suspension training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
Study: NCT04719715

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays
Description: Measurement and evaluation of the ANCA testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays
Description: Measurement and evaluation of the ANCA testing
Study: NCT05192395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001
Study: NCT06202911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral n-acetyl cysteine
Description: the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will receive placebo
Study: NCT05192395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202101
Description: DWC202101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202101
Description: DWC202101
Study: NCT06498726

Intervention type: DEVICE
Intervention: transcranial doppler
Description: Demographic and procedural variables will be extracted from medical record assistants , and analysis of recorded images TCD, MRA ,interpretation reports will be assessed , Completeness of protocol components will be assessed Data accuracy and protocol fidelity will be ensured through site monitoring
Study: NCT04093557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orton Score
Description: Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orton Score
Description: Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.

Intervention type: OTHER
Group type: OTHER
Intervention: Typical Standard of Care
Description: Clinician usual practice of prescribing bowel preps to patient
Study: NCT05162755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029
Description: S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S95029 and Sym021
Description: Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029 and Sym021 and anti-HER2 therapy
Description: Patients will be administered with S095029, Sym021 and anti-HER2 therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab
Description: Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
Study: NCT06643637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Capsule containing active ingredient, psilocybin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active ingredients
Study: NCT05765825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serplulimab
Description: Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy (TRT)
Description: Participants will receive concurrent low-dose radiotherapy treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle, third cycle（ For patients with primary lung lesions (intrathoracic lesions) evaluated as small PR (tumor shrinkage \< 80%)/SD/PD），forth cycle（for subjects evaluated as PD/SD/PR with extrathoracic residual metastases).
Study: NCT04910243

Intervention type: OTHER
Intervention: Questionnaire Survey
Description: Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.

Intervention type: OTHER
Intervention: Questionnaire Survey
Description: Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
Study: NCT06255600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Definition-transcranial Direct Current Stimulation
Description: High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Definition-transcranial Direct Current Stimulation
Description: High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High Definition-transcranial Direct Current Stimulation
Description: High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella Pyrenoidosa
Description: functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella Pyrenoidosa
Description: functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Chlorella Pyrenoidosa
Description: functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)
Study: NCT06721637

Intervention type: COMBINATION_PRODUCT
Intervention: Group A (n = 20): received core stability exercise trained three times a week for 8 weeks.
Description: Woman was in crook lying position with feet flat on the treatment table. The therapist put his two thumbs on the anterior superior iliac spines then, asked the woman to contract the abdominal muscle, hold the contraction for 10 seconds, then, asked her to relax for 10 seconds

Intervention type: DEVICE
Intervention: Group B (n = 20): received whole body vibration trained three times a week for 8 weeks
Description: The woman assumed a full squat position on a vibration platform. The apparatus was set at a frequency of 30 Hz, amplitude of 2 mm, and duration of 5 min. The women were instructed to remain in the squatting position with holding hand rail after turning on the vibration and to report any discomfort that might arise. At the end of 5 min, the vibration turned off automatically. Thereafter, the women took a 1-min rest. They were then asked to stand on the vibration platform for 5 min, with the same parameters as those used in the squatting position. Thus, the total time for the application of WBV in each session was 10 min
Study: NCT06730724

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06730659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHT101
Description: CHT101: CD 70 UCAR T
Study: NCT05964127

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air flow device
Description: An air/powder device for surface decontamination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air flow device
Description: An air/powder device for surface decontamination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand instruments
Description: Periodontal hand instruments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access flap surgery
Description: To improve the surgical access for implant decontamination
Study: NCT04909372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labelling
Description: Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact.
Study: NCT06486285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory-cognitive dual-task training (ACDT)
Description: The components of auditory training are designed based on an auditory training and aural rehabilitation program LACETM (Listening \& Communication Enhancement) developed by our study team member. The cognitive training was developed and tested feasible and valid in our study team's previous dual-task Zumba cognitive training.
Study: NCT06500650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred Occupational Therapy Intervention
Description: Person-centred Occupational Therapy Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred Occupational Therapy Intervention
Description: Person-centred Occupational Therapy Intervention
Study: NCT06125899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emhGAP-Age
Description: * Adapted emhGAP-IG;~* Adapted Problem-Solving Therapy (PST-PC)~* Support/supervision of lay providers~* Links to social support resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: emhGAP-Age
Description: * Adapted emhGAP-IG;~* Adapted Problem-Solving Therapy (PST-PC)~* Support/supervision of lay providers~* Links to social support resources.
Study: NCT04930705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with TempSure Applicator
Description: Subjects will receive up to 5 treatments on the abdomen.
Study: NCT05859438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication aid support
Description: Support to use voice input voice output communication aids
Study: NCT06062199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training in the A-DIVA scale and its failure prediction score
Description: Nurses are trained in the A-DIVA scale and its predictive failure score. This score enables them to adapt their approach to peripheral venous line insertion.
Study: NCT06258954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D reconstruction
Description: 3D reconstruction based on CT data and It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size of the DLT for lung isolation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional method for selecting double lumen tube
Description: In control group, the size of DLT is based on patient's sex and height.
Study: NCT05239117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenhyage
Description: Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenhyage
Description: Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenhyage
Description: Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter.
Study: NCT05109936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenuric
Description: Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), hypo-uricemic treatment, for a period of 2 x 6 weeks
Study: NCT04565483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Prefilled Syringe
Description: Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
Study: NCT04876313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Nab-paclitaxel
Description: 4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg IV Q3W x 13 cycles
Study: NCT05777564

Intervention type: OTHER
Group type: OTHER
Intervention: High intensity exercise
Description: High intensity exercise on a indoor aerobic exercise device.
Study: NCT06345014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-89 [Uro-Vaxom® Capsule]
Description: Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OM-89 Placebo [Uro-Vaxom® Capsule Placebo]
Description: Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
Study: NCT05635422

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: isokinetism test
Description: measure of muscular fatigability by isokinetism
Study: NCT05328024

Intervention type: DRUG
Intervention: Immunotherapy
Description: anti-PD1
Study: NCT06296004

Intervention type: DEVICE
Intervention: Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S
Description: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US

Intervention type: DEVICE
Intervention: Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S
Description: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US
Study: NCT05559671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Subunit (HZ/su) Vaccine
Description: Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Subunit (HZ/su) Vaccine
Description: Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.